This website is intended for healthcare professionals only.
ADVANCES IN MPACA CARE:
TREATMENT DECISION-MAKING IN 1L
Profesor Prager MD, PhD Director of the GI Cancer Program of the Department of Medical Oncology, Medical University of Vienna and Comprehensive Cancer Center, Vienna
Profesor Seufferlein MD, PhD Chairman of the Committee for Cancer Prevention of the German Cancer Aid and spokesman of many organizations including the Oncological Guidelines Program of the DKG
This webinar focuses on treatment decision-making in 1L mPDAC. First, the speakers consider where things stand today, reviewing epidemiological data and speaking to potential therapeutic sequences. Following this introduction, a patient case is presented. Throughout the case, the speakers share their expert insights, as well as reviewing key clinical evidence and explaining how it plays into their treatment decision.
Key points covered
This webinar considers how the latest advances in care impact treatment decision-making in 1L mPDAC. It covers the following points:
Three regimens have emerged over the past 15 years, providing new options for the management of mPDAC1—4
NALIRIFOX is the most recent to emerge, having demonstrated clinical benefit in the NAPOLI-3 phase 3 trial (2023)4*
NALIRIFOX has also been assessed in a real-world setting in Austria (exploratory analysis)5
A patient case is also presented during the webinar. During the case presentation, the speakers explain that, given the supporting evidence and considering their expert experience, NALIRIFOX can be an appropriate treatment option for patients in 1L mPDAC.6
NALIRIFOX indication: Nanoliposomal irinotecan in combination with oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas; in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine-based therapy.6
Footnote:
*In NAPOLI-3, NALIRIFOX significantly increased median overall survival vs nab-paclitaxel and gemcitabine in the intention-to-treat population (N=770, primary analysis at 23 July 2022 cut-off), (HR: 0.83 (95% CI: 0.70–0.99), P=0.036.4
References:
1. Conroy T et al. N Engl J Med. 2011;364:1817–25. 2. Von Hoff D et al. N Engl J Med. 2013;369:1691–703. 3. Goldstein D, et al. J Natl Cancer Inst. 2015.31;107(2):dju413. 4. Wainberg Z et al. Lancet. 2023;402(10409):1272–1281. 5. Reichinger A et al. Ann Oncol. 2024;35:2_suppl, S929. 6. Nanoliposomal irinotecan Summary of Product Characteristics.
Webinar highlights
Full Webinar Replay
Featured Speakers
Profesor Prager
Profesor Prager MD, PhD is the Director of the GI Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center, Vienna. He leads the Unit for Precision Medicine in Cancer and is an Associate Professor of Medicine, Board Certified for Internal Medicine, Hematology, and Medical Oncology. Prof Prager graduated from the Medical School of the University of Vienna and completed his postdoctoral training at the University of California, San Diego, USA and was a Visiting Professor at the Norris Cancer Center, University of Southern California, Los Angeles, USA in 2011. Prof Prager’s main research interests focus on translational research and (tumor-) angiogenesis and his work was honored by more than 20 international awards and published in highly renowned international journals. Prof Prager is also a member of the ESMO Scientific Committee.
Profesor Seufferlein
Profesor Seufferlein MD, PhD obtained his doctorate at the II. medical clinic of the Klinikum Rechts der Isar of the Technical University of Munich. From Berlin he moved to London where he worked at the Imperial Cancer Research Fund (now: Cancer Research UK) as a postdoc in the laboratory of Dr. E. Rozengurt for several years. After his postdoctoral period, he continued his clinical activities in Ulm at the Department of Internal Medicine I and obtained the specialist degree in Internal Medicine and the specialization in Gastroenterology. His scientific work focuses on gastrointestinal tumors, especially pancreatic cancer.
